RAPT Therapeutics and Shanghai Jemincare Pharmaceutical - GlobeNewswire
RAPT Therapeutics and Jemincare entered an exclusive license agreement for JYB1904 (RPT904), a half-life extended anti-IgE monoclonal antibody. RAPT gains worldwide rights excluding China, paying Jemincare $35M upfront, up to $672.5M in milestones, and royalties. Jemincare conducts Phase 2 trials in asthma and chronic spontaneous urticaria in China, while RAPT plans a Phase 2b trial in food allergy in 2025.
Highlighted Terms
Related News
RAPT Therapeutics and Jemincare entered an exclusive license agreement for JYB1904 (RPT904), a half-life extended anti-IgE monoclonal antibody. RAPT gains worldwide rights excluding China, paying Jemincare $35M upfront, up to $672.5M in milestones, and royalties. Jemincare conducts Phase 2 trials in asthma and chronic spontaneous urticaria in China, while RAPT plans a Phase 2b trial in food allergy in 2025.